Studying of Some Immunological Parameters in Patients with Inflammatory Bowel Disease ( IBD ) in Al-Anbar Province | ||
| Journal of University of Anbar for Pure Science | ||
| Article 1, Volume 15, Issue 1, April 2021, Pages 1-7 PDF (684.25 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.37652/juaps.2022.172396 | ||
| Authors | ||
| Thikra AL-Obaidy* 1; Hasan Ali Mutar2; Thaer Abdulqader Salih3 | ||
| 1Department of Biology, College of Sciences, University of Anbar, Ramadi, Iraq | ||
| 2Department of Animal Production, College of Agriculture, University of Anbar, Ramadi, Iraq | ||
| 3Department of Biology, College of Education for Pure Sciences, University of Anbar, Ramadi, Iraq | ||
| Abstract | ||
| The serum levels of interlukine-17A and interlukine-17F were determined using ELISA technique for quantitative determination of IL-17A and IL-17F concentrations in serum. A comparison in Immunological parameters between the two groups (patients and control) showed that there was a significant difference in levels of IL-17 A and IL-17F with p-value (<0.05). The means were: IL-17 A (79.29 pgml),( 18.72 pgml ) and IL-17F(226.4 pgml ),( 29.09 pgml ) respectively. Also the serum levels of p ANCA and c ANCA were determined using Enzyme-linked immunosorbent assay ELISA technique for quantitative determination of pANCA and c ANCA concentrations in human serum. There was a significant difference in levels of perinuclear antineutrophil cytoplasmic antibodies (pANCA) and cytoplasmic antineutrophil cytoplasmic antibodies(c ANCA ) with p-value(<0.05), the means were: pANCA ( 60.93 ngml), (10.31ngml), and c ANCA (35.78 ngml), (8.341ngml) respectively. | ||
| Keywords | ||
| p ANCA; c NCA; IL-17A; IL-17F | ||
| References | ||
|
[1] McCurley N., Hirano M., Das S., and Cooper M. (2012)."Immune related genes underpin the evolution of adaptive immunity in jawless vertebrates. Curr Genomics". 13; 86-94.
[2] Murphy K.,and Stockinger B. (.2010). "Effector T cell plasticity: flexibility in the face of changing circumstances". Nat Immunol.11;674-680.
[3] Fujino S., Andoh A., and Bamba S. (2003). "Increased expression of interleukin 17 in inflammatory bowel disease". Gut. 52;65- 70.
[4] Seiderer J., Elben I.,and Diegelmann J. (2008). "Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD". Inflamm Bowel Dis.14;437-445.
[5] Kobayashi T., Okamoto S.,and Hisamatsu T. (2008). "IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease". Gut.57;1682-1689.
[6] Raza A., andShata M. (2012). "Letter: pathogenicity of Th17 cells may differ in ulcerative colitis compared with Crohn’s disease". Aliment Pharmacol Ther.36;204.
[7] Halbwachs L., Nusbaum P., andNoel L.(1992). "Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis". Clin Exp Immunol.90;79-84.
[8] Kain R., Matsui K.,and Exner M.(1995). "A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a relatedmembrane protein in glomerular endothelial cells". Journal of Experimental Medicine.181(2);585–597.
[9] Savige J., Davies,D.and Gatenby P. (1994). "Anti-neutrophil cytoplasmic antibodies (ANCA): their detection and significance: report fromworkshops. "Pathology.26(2);186– 193.
[10] Kallenberg C., Shoenfeld Y., Gershwin M., and Meroni P. (2007). "Antineutrophil antibodies with specificity for Myeloperoxidase in Autoantibodies. "Elsevier, Oxford, UK. 2nd edition;95–103.
[11] Jennette J. (1991). "Anti-neutrophil cytoplasmic autoantibody-associated disease: A pathologist's perspective". Am J Kidney Disease.18;164-170.
[12] Radice A., Sabadini E., and Sinico A. (2007). "Antineutrophil antibodies with specificity for Proteinase 3. in Autoantibodies".Elsevier, Oxford, UK, 2nd edition;105–110.
[13] Kaneko K., Suzuki Y., Yamashiro Y., Yabuta K. (1993). "Is pANCA in ulcerative colitis directed against b-glucuronidase? " Lancet;341: 320.
[14] Birgit T., Ulrich S., Tilman S.,and Howard J.(2000). "Atypical p-ANCAÓ in IBD and Hepatobiliary Disorders React With a 50-Kilodalton Nuclear Envelope Protein of Neutrophilsand Myeloid Cell Lines.Gastroenterology".119;310–322.
[15] Papp M., Altorjay I., Lakos G., Tumpek J., Sipka S., Dinya T. (2009). "Evaluation of the combined application of ethanol-fixed and formaldeyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Clin Vaccine Immunol".16(4);464–70.
[16] Lochman I., Kral V., Lochmanova A., Lupač J., and Cebecauer L. (2011). "ANCA in the diagnosis of neutrophil-mediated inflammation. Autoimmun ".Rev.10;295–8.
[17] Mokhtarifar A., Ganji A., Sadrneshin M., Bahari A., Esmaeilzadeh A.,and Ghafarzadegan K.. (2013). "Diagnostic value of ASCA ant atypical p-ANCA in differential diagnosis of inflammatory bowel disease". Middle East J Dig Dis.5;93–7.
[18] Faber V., Elling P. (1967). "Leukocyte-specific antinuclear factors in patients with Felty's syndrome, rheumatoid arthritis, systemic lupus erythematosus and other diseases". Acta Med Scand.179;257.
[19] Nielsen H., Wiik A., and Elmgreen J. (1983). "Granulocyte specific antinuclear antibodies in ulcerative colitis". Acta Pathol Microbiol Immunol Scand.91;23.
[20] Charles L., Falk R., and Jennette J . (1989). "Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells. Clin Immunol Immunopathol.53;243.
[21] Israeli E., Grotto I., Gilburd B., Balicer R., Goldin E., and Wiik A.(2005). Anti- Saccharamyces cerevisiae antibodies as predictors of inflammatory bowel disease". Gut.54;1232–6.
[22] Vasiliauskas E., Kam L., Karp L., Gaiennie J., Yang H., Targan S. (2000). "Marker antibody expression stratifies Crohn's disease into immunologically homogenous subgroups with distinct clinical characteristics". Gut.47;487–96.
[23] Zhang L., Ren J., Wong C., Wu W., Ren S.,andShen J. (2012). "Effects of cigarette smoke and its active components on ulcer formation and healing in the gastrointestinal mucosa". Curr Med Chem.19;63–9.
[24] Cadman H. (2010).Aspect of phlebotomy .In: WHO guidelines on drawing blood: best practices in phlebotomy.Sign;8-47.
[25] Yang X., Panopoulos A.,andNurieva R.( 2007). "STAT3 regulates cytokine-mediated generation of inflammatory helper T cells". J. Biol. Chem.282(13); 9358–9363.
[26] Hyun Y., Han D., Lee A., Eun C., Youn J.,andKim H. (2012). "Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis".33; 931-936.
[27] Afzali B., Lombardi G., Lechler R., Lord G. (2007). "The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease". Clin Exp Immunol.148; 32-46
[28] Ohman L., Dahlén R., Isaksson S., Sjöling A., Wick M., Sjövall H., Van Oudenhove L., Simrén M., and Strid H. (2013). "Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease". Inflamm Bowel Dis.19;2433-2439.
[29] Jiang W., Su J., Zhang X., Cheng X., Zhou J.,andShi R.(2014). "Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflammation research : official journal of the European Histamine Research Society".63(11);943-50.
[30] Qingdong G.,and Jiguo Z. (2017). "Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease". Mediators of Inflammation;1-8.
[31] Cua D.,andTato C. (2010). "Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol".10;479-489.
[32] Zheng Z., Wan X.,andLiu L.( 2011). "Serum contents of IL-23 and IL-17 in the patients with ulcerative colitis and the clinical significance". Xibao Yu Fenzimianyixue Zazhi.27; 203-206.
[33] Zhou G., Song Y., and Yang W. (2016). "ASCA, ANCA, ALCA and many more: are they useful in the diagnosis of inflammatory bowel disease?,” Digestive Diseases".34.1-2; 90–97.
[34] Bouzid D., Haddouk S., Amouri A., Ben HadjHmida Y., Tahri N, and Masmoudi H. (2011). "Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Indian J Gastroenterol".30;229-32.
[35] Prideaux L., de Cruz P., Ng S., and Kamm M. (2012). "Serological antibodies in inflammatory bowel disease: a systematic review,” Inflammatory Bowel Diseases".18( 7);1340–1355.
[36] Julia S., Ira Elben, Julia D., Glas, M.,andJohannes S. (2008). "Role of the Novel Th17 Cytokine IL-17F in Inflammatory Bowel Disease (IBD)Upregulated Colonic IL-17F Expression in Active Crohn’s Disease and Analysis of the IL17F p.His161Arg Polymorphism in IBDInflamm Bowel Dis".14( 4);437-445.
[37] Franke A., Hampe J.,and Rosenstiel P. (2007). "Systematic association mapping identifies NELL1 as a novel IBD disease gene". PLoS ONE.2; e691.
[38] Cambridge G., Rampton D., Stevens T., McCar thy D., Kamm M, and Leaker B. (1992). "Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role". Gut .33;668-674.
[39] Zauli D., Ghetti S., and Grassi A. (1997). "Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis". Hepatology.25;1105-1112.
[40] Rutgeerts P., and Vermeire S. (1998). "Clinical value of the detec-tion of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease". Gastroenterology.115;1006-9.
[41] Kader H., Ruchelli E., and Maller E. (1998). "Langerhans cell histiocytosis and stool retention caused by a perianal mass". J Pediatr Gastroenterol Nutr .26;226–8.
[42] Dotan I. (2007). "Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification". Expert Rev Gastroenterol Hepatol.1; 265-274.
[43] ZHI Z., KE S. and JIE P. (2017). "Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype". Biomedical Reports. 6; 401-410.
[44] Gross W., Schmitt W.,and Csernok E. (1993). "ANCA and associated diseases: immunodiagnostic and pathogenetic aspects". Clin Exp Lmmunol.91;1-12.
[45] Shanahan F., Duerr R., Rotter J., Yang H., Sutherland L., McElree C., Landers C.,and Targan S.(1992). "Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology".103;456-461.
[46] Napolitano G., Perri F., Conoscitore P.,and Andriulli A. (2000). "Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: clinical role and review of the literature. Dis Colon Rectum".43; 999-1007.
[47] Peeters M., Joossens S., Vermeire S., Vlietinck R., Bossuyt X., and Rutgeerts P. (2001). "Diagnosticvalue of anti-Saccharomycescerevisiae and antineutrophilcytoplasmicautoantibodies in inflammatory bowel disease". Am J Gastroenterol.96;730-4.
[48] Abu-Freha N., Wafi B., Ina S., Muhammad Abu T., Ohad E., Jaber E., Afzali B., Lombardi G., Lechler R., Lord G. (2007). "The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease". Clin Exp Immunol.148;32-46.
[49] Saibeni S., andGBorsi M. (2003). "Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases Author links open overlay panel.Digestive and Liver Disease" .35(12);862-868
[50] Zhou F., Xia B., and Wang F. (2010). "The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China” .Clinica Chimica Acta.411(20); 1461–1465. | ||
|
Statistics Article View: 112 PDF Download: 121 |
||